000			01387nam a2200253Ia 4500
003			MX-MdCICY
005			20250625160222.0
040			_cCICY
090			_aB-18018
245	1	0	_aA patent review of FGFR4 selective inhibition in cancer (2007-2018)
490	0		_vExpert Opinion on Therapeutic patents, 29(6), p.429-438, 2019
520	3		_aFGFR4 is a tyrosine kinase receptor which, under physiological conditions, is activated upon ligand binding in a highly regulated manner. This triggers downstream signaling related to proliferation and apoptosis resistance as well as other physiological processes. Many molecular alterations of the receptor and its ligands, specially FGF19, have been reported in several types of cancer, with special relevance in hepatocellular carcinoma. In addition, these have also been detected in other solid malignancies, including lung, breast, or colon cancer, among others.
650	1	4	_aFGFR4
650	1	4	_aCANCER
650	1	4	_aINHIBITOR
650	1	4	_aHEPATOCELLULAR CARCINOMA
700	1	2	_aQuintanal-Villalonga, A.
700	1	2	_aFerrer, I.
700	1	2	_aMolina-Pinelo, S.
700	1	2	_aPaz-Ares, L.
856	4	0	_uhttps://drive.google.com/file/d/1fd9aE7n2LpfbCxBPP4ayEP1IPNUWT22D/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c52177 _d52177